A kayaker from Dartmouth was suspended by the Canadian Centre for Ethics in Sport for an anti-doping rule violation.
Austin Denman, who has competed in world and international championships in kayaking, received a two-month sanction rendering him ineligible from competitions between Dec. 16 and Feb. 16.
Denman’s urine sample, collected during out-of-competition doping control on July 19, 2013, revealed the presence of terbutaline, a prohibited beta-2 agonist. It's a class of drug that causes muscle relaxation and is primarily used to treat asthma and other pulmonary disorders.
In response to the centre’s notification of the finding, Denman exercised his right to a hearing under the rules of the Canadian Anti-Doping Program in London, Ont.
The arbitrator Richard McLaren found that Denman, who suffers from asthma, did not intend to use terbutaline to enhance athletic performance.
Denman, who was in a period of doping control, had been required to apply for a clearance for the drug, which he failed to do before his April 25 deadline. Denman said in the hearing he simply forgot to apply for it.
He also forgot failed to declare his use of the inhaler on his Doping Control Form.
By the time of the hearing, his ‘Therapeutic Use Exemption’ had been granted.
Denman had also participated in standard anti-doping education and training in spring of 2013.
“To find that he is not at fault at all could in my mind have a detrimental impact on the fight against doping in sport,” said McLaren in the decision.
The CCES is an independent, national, not-for profit organization with a responsibility to administer the Canadian Anti-Doping Program.
Under the CADP rules, the CCES announces publicly every anti-doping rule violation.